Post by : Badri Ariffin

A biotechnology firm from the US, Revolution Medicines, has revealed promising data regarding an innovative oral medication that may signify a significant shift in advanced pancreatic cancer treatment.

Known as daraxonrasib, this once-daily drug has shown remarkable enhancements in patient outcomes during an expansive Phase 3 clinical trial with around 500 participants. The company reports a 60 percent decrease in mortality risk compared to conventional chemotherapy, alongside a doubling of the average survival duration.

Experts believe the drug’s success is attributable to its capability to specifically target mutations in the RAS gene, which play a vital role in the development and advancement of multiple cancer types, including pancreatic cancer.

Brian Wolpin, a Professor at Harvard Medical School and the primary investigator of the research, framed these results as a significant step forward in cancer care. He suggested that this new treatment paradigm could transform clinical practices, especially for individuals whose illness progresses despite chemotherapy.

Revolution Medicines intends to submit the clinical trial results to the US Food and Drug Administration (FDA) for expedited approval, aiming to fast-track the release of promising new therapies for serious medical conditions.

Should daraxonrasib receive approval, it may bring renewed optimism to patients facing one of the most aggressive and challenging cancer forms.

#world news #Global News #World Update #Health News